{
  "abstract": "Background and Importance Autologous chimeric antigen receptor (CAR) T-cell therapies have demonstrated significant clinical benefit in patients with chemo refractory aggressive B-cell lymphomas or myeloma. Emerging evidence suggests that delayed CAR T-cell infusion, including prolonged time from leukapheresis to infusion, known as vein-to-vein time (V2Vt), may adversely impact clinical outcomes.Aim and Objectives This study aimed to evaluate real-world V2Vt in patients receiving autologous CAR T-cell therapies at a tertiary oncology centre, and to compare differences across available products.Material and Methods Requests for CAR T-cell therapies and administration records received by the hospital pharmacy were reviewed to determine the number of therapies administered and V2Vt. Treatments administered between 1 January 2021, and 31 December 2024, were included. V2Vt was expressed in days as mean ± standard deviation and median values for each product. Data normality was assessed using the D’Agostino-Pearson omnibus test. Since distributions were not Gaussian, the Kruskal-Wallis test was used to compare differences among groups. When the overall test was significant, post hoc pairwise comparisons were performed using Dunn’s multiple comparison test (significance level p<0.05). Statistical analyses were conducted using GraphPad Prism 8.Results A total of 73 CAR T-cell therapies were administered during the study period, increasing from nine (12%) in 2021 to 36 (49%) in 2024. Specifically, 31 (42%) were axicabtagene ciloleucel (axi-cel), 31 (42%) tisagenlecleucel (tisa-cel), and 11 (16%) brexucabtagene autoleucel (brexi-cel). Mean V2Vt was 48±19 days (median 42) for axi-cel, 67±29 days (median 57) for tisa-cel, and 53±35 days (median 41) for brexi-cel. The Kruskal-Wallis test showed a significant overall difference (p=0.002), with Dunn’s post hoc test indicating significant differences between axi-cel and tisa-cel (p=0.003), and between tisa-cel and brexi-cel (p=0.035).Conclusion and Relevance V2Vt varied significantly among CAR T-cell products, with axi-cel showing the shortest mean time. Manufacturing and logistical delays remain key barriers to ensure timely treatment. Decentralised manufacturing and off-the-shelf allogeneic platforms may reduce waiting times and costs. In this evolving scenario, hospital pharmacists play a pivotal role in process optimisation, ensuring timely access to advanced therapies.References and/or Acknowledgements 1. Bryla A, et al. Involvement of the hospital pharmacist in securing the chimeric antigen receptor (CAR)-T cell circuit. Eur J Hosp Pharm. 2025 Mar 6:ejhpharm-2024-004454.Conflict of Interest No conflict of interest",
  "authors": [
    {
      "affiliations": [
        "University of Palermo, Department of Biological- Chemical and Pharmaceutical Sciences and Technologies Stebicef, Palermo, Italy"
      ],
      "name": "M Gallina"
    },
    {
      "affiliations": [
        "Oncology Department ‘La Maddalena’, Hospital Pharmacy, Palermo, Italy"
      ],
      "name": "GC Marengo"
    },
    {
      "affiliations": [
        "Oncology Department ‘La Maddalena’, Hospital Pharmacy, Palermo, Italy"
      ],
      "name": "S Bonanno"
    },
    {
      "affiliations": [
        "Oncology Department ‘La Maddalena’, Hospital Pharmacy, Palermo, Italy"
      ],
      "name": "I Barberi"
    },
    {
      "affiliations": [
        "Oncology Department ‘La Maddalena’, Haematology and Bone Marrow Transplant Unit, Palermo, Italy"
      ],
      "name": "M Musso"
    }
  ],
  "title": "2SPD-025 Investigating vein-to-vein time in autologous chimeric antigen receptor T-cell therapies: a real-world analysis",
  "uid": "7cedef39-0fed-59b9-a093-2e32b3d9f6bb"
}